3rd Quarter - Report

ALLERGAN USA, INC. for ALLERGAN USA, INC.

Firm
Client
Income
—
Expenses
$510,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 22, 2012 $380,000 Replaced
3rd Quarter - Report (this page) Jan 18, 2013 $510,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues

LobbyistCovered position, as disclosed
G THOMAS LONG —
TED PIPER —
ASHLIE VAN METER —

Contacted: Office of Management & Budget (OMB); Federal Communications Commission (FCC); SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Deficit Reduction Act (P.L. 109-171): Medicare and Medicaid Provisions Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies; Fuding of FDA; S3187, HR 5651

LobbyistCovered position, as disclosed
G THOMAS LONG —
TED PIPER —
ASHLIE VAN METER —

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Federal Communications Commission (FCC); SENATE

Bills named: H.R. 5651 (112th)

Telecommunications TEC

Junk Fax regulations and interpretations, and rule promulgations

LobbyistCovered position, as disclosed
G THOMAS LONG —
TED PIPER —
ASHLIE VAN METER —

Contacted: Office of Management & Budget (OMB); Federal Communications Commission (FCC); SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

S. 23, H.R.1249, The America Invents Act S. 27 Preserve Access to Life Saving Medicine Act Patient Protection and Affordable Care Act S. 1882, Fair and Immediate Release of Generic Drug Act

LobbyistCovered position, as disclosed
G THOMAS LONG —
TED PIPER —
ASHLIE VAN METER —

Contacted: SENATE; Federal Communications Commission (FCC); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: S. 23 (112th), S. 1882 (112th), S. 27 (112th), H.R. 1249 (112th)

Health Issues HCR

The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296); H.R.2245,Preserving Access to Life-Saving Medications Act of 2011

LobbyistCovered position, as disclosed
G THOMAS LONG —
TED PIPER —
ASHLIE VAN METER —

Contacted: Office of Management & Budget (OMB); Federal Communications Commission (FCC); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2245 (112th), H.R. 1483 (112th), S. 296 (112th), H.R. 1316 (112th), H.R. 1065 (112th)

Medical/Disease Research/Clinical Labs MED

Kidney Disease Education governement partnership opportunities for research and development

LobbyistCovered position, as disclosed
G THOMAS LONG —
TED PIPER —
ASHLIE VAN METER —

Contacted: SENATE; Federal Communications Commission (FCC); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.